MLS-101
Mineralys Therapeutics
[]
mineralys therapeutics presents positive lorundrostat results from the phase 2 target-htn trial at acc.23/wcc $mlys 
Real-Time News, Market Data and Stock Quotes for Biotech, Pharma, and Healthcare Stocks